跳至主要内容
临床试验/NCT02541955
NCT02541955
已完成
4 期

Use of Acthar in Rheumatoid Arthritis Related Flares

Veena Ranganath, MD, MS1 个研究点 分布在 1 个国家目标入组 40 人2017年7月20日
干预措施Acthar
相关药物Acthar

概览

阶段
4 期
干预措施
Acthar
疾病 / 适应症
Rheumatoid Arthritis (RA)
发起方
Veena Ranganath, MD, MS
入组人数
40
试验地点
1
主要终点
DAS28
状态
已完成
最后更新
2个月前

概览

简要总结

This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.

详细描述

Participants with active RA flair will be assigned to take on one of two Acthar doses, either 40 units per week or 80 units twice a week. Both arms will be taking the drug for 4 weeks. Each participant will be coming back for visits at 2 weeks, 1 month and 3 months after the initial baseline visit. During these visits the following information will be collected: MSUS of joints, DAS28, Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data 3 (RAPID3) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Participants will also be asked to fill out a questionnaire about their health status. Efficacy of Acthar to decrease evidence of MSUS synovitis and disease activity measures will be analyzed using the above mentioned instruments, as well as Acthar's ability to prevent the necessity to change patients' RA treatment regimen.

注册库
clinicaltrials.gov
开始日期
2017年7月20日
结束日期
2025年5月20日
最后更新
2个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Veena Ranganath, MD, MS
责任方
Sponsor Investigator
主要研究者

Veena Ranganath, MD, MS

Assistant Clinical Professor

University of California, Los Angeles

入排标准

入选标准

  • Patient must meet 1987 ACR criteria
  • Age \> 18 years of age
  • Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) \>=3.2
  • Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Stable prednisone \<10mg or equivalent
  • Power Doppler score of \>=10

排除标准

  • Prior treatment with Acthar in the past 2mos
  • Meet one of the above RA flare requirements
  • Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

研究组 & 干预措施

40 Units

40 units of Acthar per week

干预措施: Acthar

80 Units

80 units of Acthar twice per week

干预措施: Acthar

结局指标

主要结局

DAS28

时间窗: Baseline to 2 Weeks

DAS28 will be calculated. The change in the scores will be analyzed between the two groups.

Ultrasound Power Doppler Score

时间窗: Baseline to 2 Weeks

Using Ultrasound a measure of Power Doppler will be calculated. The change in the scores will be analyzed between the two groups.

次要结局

  • Ultrasound Grey Scale Synovial Hypertrophy score(Baseline to 2 Weeks)
  • HAQ-DI(Baseline to 4 Weeks)

研究点 (1)

Loading locations...

相似试验